FIM
PGNX

Freedom Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Freedom Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-56,745
Closed -$423K – 1190
2018
Q1 		$423K Buy
+56,745
New +$377K 0.02% 706

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Freedom Investment Management's PGNX Position: Q2 2018 in Review

Freedom Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2018, closing a stake of 56,745 shares — an estimated $423K sold.

Freedom Investment Management first reported a position in PGNX in Q1 2018 and held it in 1 quarter. The position peaked at $423K in Q1 2018. 155 funds tracked by Wall St. Rank hold PGNX as of Q2 2018.

  • Freedom Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Freedom Investment Management sold 56,745 Progenics Pharmaceuticals Inc shares in Q2 2018, an estimated $423K.
  • Freedom Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 1 quarter.
  • Freedom Investment Management's Progenics Pharmaceuticals Inc position peaked at $423K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2018.

Based on Freedom Investment Management's 13F filing for Q2 2018, filed 27 Jul 2018.